[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-355643-105":59,"doc-detail-355643-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","hla-g-in-hematological-malignancies-immunoregulatory-mechanisms-and-implications-for-immune-evasion-and-immunotherapy","HLA-G in Hematological Malignancies - Immunoregulatory Mechanisms and Implications for Immune Evasion and Immunotherapy","","Human leukocyte antigen G (HLA-G) is a nonclassical MHC class I molecule linked to unfavorable prognosis and emerging immunotherapeutic relevance in hematological malignancies. Limited genetic diversity and multiple isoforms enable immune tolerance in immunoprivileged tissues and abnormal upregulation in disease, including cancer. Elevated HLA-G supports tumor immune evasion and affects outcomes in leukemia, lymphoma, and multiple myeloma. HLA-G polymorphisms, notably the 14-base pair insertion/deletion, associate with susceptibility, progression, and adverse prognosis. Specific genotypes correlate with increased membrane-bound and soluble HLA-G, impaired immune surveillance, and reduced survival, especially in chronic lymphocytic leukemia. Inflammatory cytokines such as interferon-γ may further shape suppressive microenvironments. Acting as a nonclassical immune checkpoint, HLA-G suggests targets for checkpoint blockade combinations and CAR-T approaches, while informing prognostic biomarkers and therapy to restore antitumor immunity.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/hla-g-in-hematological-malignancies-immunoregulatory-mechanisms-and-implications-for-immune-evasion-and-immunotherapy/355643/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/hla-g-in-hematological-malignancies-immunoregulatory-mechanisms-and-implications-for-immune-evasion-and-immunotherapy/355643.png","ImageObject",300,407,{"name":92,"@type":93},"Melati","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",13,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What role does HLA-G play in hematological malignancies?","Question",{"text":113,"@type":114},"HLA-G is a nonclassical MHC class I molecule whose increased expression is associated with unfavorable prognosis. It contributes to immune tolerance and tumor immune evasion in leukemia, lymphoma, and multiple myeloma.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How do HLA-G genetic polymorphisms affect disease outcomes?",{"text":118,"@type":114},"Polymorphisms in regulatory regions of the HLA-G gene, including the 14-base pair insertion/deletion, have been linked to cancer susceptibility, disease progression, and adverse prognosis. Certain genotypes correlate with higher membrane-bound and soluble HLA-G levels, impaired immune surveillance, and reduced survival, particularly in chronic lymphocytic leukemia.",{"name":120,"@type":111,"acceptedAnswer":121},"How might HLA-G be targeted for immunotherapy?",{"text":122,"@type":114},"As a nonclassical immune checkpoint, HLA-G is proposed as a target for immune checkpoint blockade combinations. It may also be used in CAR-T cell strategies directed against HLA-G-expressing malignant cells, aiming to restore effective antitumor immunity.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},355643,1790177925,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":41,"preview_page_count":19,"preview_urls":146},962085570644,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Journal of Immunology Research  \nREVIEW ARTICLE OPEN ACCESS  \nHLA-G in Hematological Malignancies: Immunoregulatory Mechanisms and Implications for Immune Evasion and Immunotherapy  \nThaís Lohana Chanel Pereira Ribeiro1, 2 | Glenda Menezes Nogueira1, 2, 3 | Mateus Souza-Barros1, 3 | Júlia Santos Moraes1, 3 | Larissa Silva Santos1, 3 | Lucas Silva Oliveira1, 3,4 | Juniel Assis Crespo-Neto1, 2 |  \nJulia Goes Souza Ghedini1  | Fábio Magalhães-Gama1, 5 | Adriana Malheiro1, 2, 3,4 | Fabíola Silva Alves-Hanna1, 2, 3  | Allyson Guimarães Costa1, 2, 3   \n1Department of Teaching and Research, Fundação Hospitalar de Hematologia e Hemoterapia do Amazonas (HEMOAM), Manaus, Brazil | 2Graduate Program in Applied Sciences in Hematology, Universidade do Estado do Amazonas (UEA), Manaus, Brazil | 3Graduate Program in Basic and Applied Immunology, Institute of Biological Sciences, Universidade Federal do Amazonas (UFAM), Manaus, Brazil | 4Graduate Program in Biotechnology, Universidade Federal do Amazonas  \n(UFAM), Manaus, Brazil | 5Graduate Program in Health Sciences, René Rachou Institute – Fundação Oswaldo Cruz (FIOCRUZ) Minas, Belo Horizonte, Brazil Correspondence: Allyson Guimarães Costa ([allyson.gui.costa@gmail.com](allyson.gui.costa@gmail.com))  \nReceived: 27 January 2026 | Revised: 4 April 2026 | Accepted: 9 April 2026  \nAcademic Editor: Poorani Gurumallesh Prabu  \nKeywords: hematological malignancies | HLA-G | immune surveillance | immunotherapy | tumor immune evasion  \nABSTRACT  \nHuman leukocyte antigen G (HLA-G) is a nonclassical major histocompatibility complex class I molecule whose increased expression has been consistently associated with unfavorable prognosis in solid tumors and has emerged as a potential immunotherapeutic target in hematological malignancies. HLA-G exhibits limited genetic diversity and generates multiple isoforms that play a critical role in immune tolerance, being physiologically expressed in immunoprivileged tissues and aberrantly upregulated in a variety of pathological conditions, including cancer. Accumulating evidence indicates that elevated HLA-G expression contributes to tumor immune evasion and inﬂuences clinical outcomes in patients with leukemia, lymphoma, and multiple myeloma. Genetic variability within the HLA-G gene, particularly polymorphisms located in regulatory regions such as the 14-base pair insertion/deletion, has been associated with cancer susceptibility, disease progression, and adverse prognosis. In hematological malignancies, speciﬁc genotypes, including the homozygous deletion variant, have been linked to increased levels of membrane-bound and soluble HLA-G, correlating with impaired immune surveillance and reduced survival, particularly in chronic lymphocytic leukemia. Moreover, HLA-G expressions maybe modulated by inﬂammatory cytokines, such as interferon-γ, further shaping the immunosuppressive tumor microenvironment. By functioning as a nonclassical immune checkpoint, HLA-G represents a promising target for innovative immunotherapeutic strategies, including immune checkpoint blockade combinationsand chimeric antigen receptor (CAR)-T cell approaches directed against HLA-G-expressing malignant cells. In this review, we summarize current knowledge regarding HLA-G expression, genetic polymorphisms, and immunoregulatory mechanisms in hematological malignancies, highlighting their clinical and translational implications. Improved understanding of HLA-G-mediated immune modulation may contribute to the development of novel prognostic biomarkers and therapeutic strategies aimed at restoring effective antitumor immunity.  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \nCopyright © 2026 Thaís Lohana Chanel Pereira Ribeiro et al. Journal of Immunology Research published by John Wiley & Sons Ltd.  \n1 | Introduction  \nHematological neopla","cbCais6TL2DR1fNA","https://ap.wps.com/l/cbCais6TL2DR1fNA","pdf",1961362,12,"English","# Introduction\n## Overview of hematological neoplasms\n## Leukemias: classification and common subtypes\n## Lymphomas: Hodgkin and non-Hodgkin categories","[{\"question\":\"What role does HLA-G play in hematological malignancies?\",\"answer\":\"HLA-G is a nonclassical MHC class I molecule whose increased expression is associated with unfavorable prognosis. It contributes to immune tolerance and tumor immune evasion in leukemia, lymphoma, and multiple myeloma.\"},{\"question\":\"How do HLA-G genetic polymorphisms affect disease outcomes?\",\"answer\":\"Polymorphisms in regulatory regions of the HLA-G gene, including the 14-base pair insertion/deletion, have been linked to cancer susceptibility, disease progression, and adverse prognosis. Certain genotypes correlate with higher membrane-bound and soluble HLA-G levels, impaired immune surveillance, and reduced survival, particularly in chronic lymphocytic leukemia.\"},{\"question\":\"How might HLA-G be targeted for immunotherapy?\",\"answer\":\"As a nonclassical immune checkpoint, HLA-G is proposed as a target for immune checkpoint blockade combinations. It may also be used in CAR-T cell strategies directed against HLA-G-expressing malignant cells, aiming to restore effective antitumor immunity.\"}]","HLA-G in Hematological Malignancies - Immunoregulatory Mechanisms and Implications for Immune Evasion and Immunotherapy | PDF",1790120264,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0544345b3ed4cbd52eb72b160a2c2f37.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3745c7d95356e0a05b5362192b62b4af.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fcde22cd7774bdbe19e6db841434f3ac.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/49c1baf4145beb258c9c6ed78ee957a9.webp",980,1287]